按结肠镜检查指征评估腺瘤与锯齿状病变检出:ADR-ESS评分
基于标准化临床文档的前瞻性队列研究,分析4个内镜中心35名内镜医师的15,253例结肠镜检查,计算各指征下腺瘤和SSL检出率。开发ADR-ESS评分,其置信区间更窄、稳定性优于ADR,腺瘤检出与SSL检出仅中度相关。
要点
- 筛查首次ADR为36.3%,监视指征腺瘤检出率更高(RR 1.22),非首次筛查更低(RR 0.80)。
- ADR-ESS评分较ADR置信区间更窄、周期波动更小,不因指征量加权或校正而改善。
- 腺瘤检出与SSL检出仅中度相关(r=0.44),腺瘤检出是SSL检出的不完美替代指标。
核心结论
- 基于标准化临床文档的自动化结肠镜审计可行,ADR-ESS评分提高了腺瘤检出评估的精确度并强调所有结肠镜指征下的质量。
研究设计与样本
- 前瞻性队列研究,纳入4个内镜中心35名内镜医师的15,253例结肠镜检查,按所有结肠镜指征计算总体及进展期腺瘤和无蒂锯齿状病变(SSL)检出率。
主要发现
- 总体筛查首次ADR为36.3%(95%CI 34.5%-38.1%)。
- 非首次筛查腺瘤检出率相对率0.80(95%CI 0.74-0.87),家族史相对率0.84(95%CI 0.74-0.96),监视相对率1.22(95%CI 1.15-1.31),FIT随访相对率1.21(95%CI 1.07-1.37)。
- 筛查首次的进展期腺瘤、SSL和进展期SSL检出率分别为6.7%(95%CI 5.7%-7.7%)、7.2%(95%CI 6.2%-8.2%)和2.6%(95%CI 2.0%-3.2%)。
- ADR-ESS置信区间较ADR显著更窄、周期间变异更小,且不因指征量加权或按指征校正检出而改善。
关键数值与推荐
- 筛查首次ADR为36.3%(95%CI 34.5%-38.1%)。
- 筛查首次进展期腺瘤检出率6.7%(95%CI 5.7%-7.7%),SSL检出率7.2%(95%CI 6.2%-8.2%),进展期SSL检出率2.6%(95%CI 2.0%-3.2%)。
临床怎么用
- 可采用基于标准化文档的自动化审计程序监测所有结肠镜指征下的病变检出率。
- ADR-ESS评分可作为提高腺瘤检出评估精确度和稳定性的工具,但不替代对SSL检出的独立关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The adenoma detection rate at screening (ADR) predicts interval colorectal cancer. Monitoring other lesion detection rates and colonoscopy indications has been proposed. We developed a comprehensive, automated colonoscopy audit program based on standardized clinical documentation, explored detection rates across indications, and developed the Adenoma Detection Rate - Extended to all Screening / Surveillance (ADR-ESS) score. METHODS: In a prospective cohort study, we calculated overall and advanced adenoma and sessile serrated lesion (SSL) detection rates among 15,253 colonoscopies by 35 endoscopists from 4 endoscopy units across all colonoscopy indications. We explored correlations between detection rates, and the precision and stability of ADR-ESS versus ADR. RESULTS: The overall "screening, first" ADR was 36.3% (95% confidence interval [CI], 34.5%-38.1%). The adenoma detection rate was lower for "screening, not first" (relative rate [RR], 0.80; 95% CI, 0.74-0.87) and "family history" (RR, 0.84; 95% CI, 0.74-0.96), and higher for "surveillance" (RR, 1.22; 95% CI, 1.15-1.31) and "follow-up, FIT" (RR, 1.21; 95% CI, 1.07-1.37). For "screening, first," the detection rates for advanced adenoma, SSL, and advanced SSL were 6.7% (95% CI, 5.7%-7.7%), 7.2% (95% CI, 6.2%-8.2%), and 2.6% (95% CI, 2.0%-3.2%), respectively. Adenoma and SSL detection were correlated (r = 0.44; P = .008). ADR-ESS had substantially narrower confidence intervals and less period-to-period variability than ADR, and was not improved by weighting for indication volume and correction for detection by indication. CONCLUSIONS: Comprehensive, automated colonoscopy audit based on standardized clinical documentation is feasible. Adenoma detection is a fair but imperfect proxy for SSL detection. ADR-ESS increases the precision of adenoma detection assessments and emphasizes quality across colonoscopy indications.
引用
- Ladabaum U, Shepard J, Mannalithara A, et al. Adenoma and Serrated Lesion Detection by Colonoscopy Indication: The ADR-ESS (ADR Extended to all Screening/Surveillance) Score. Clin Gastroenterol Hepatol. 2021. PMID: 33895358. doi:10.1016/j.cgh.2021.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。